The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers.
 
Matthew H. Taylor
Consulting or Advisory Role - ArQule; Array BioPharma; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Eisai; Loxo; Novartis
Speakers' Bureau - Bristol-Myers Squibb; Eisai
 
Justin F. Gainor
Honoraria - ARIAD; Incyte; Merck; Novartis; Pfizer; Takeda
Consulting or Advisory Role - Agios; Amgen; Array BioPharma; Bristol-Myers Squibb; Genentech; Jounce Therapeutics; Loxo; Merck; Oncorus; Regeneron; Takeda; Theravance
Research Funding - Adaptimmune (Inst); Alexo Therapeutics (Inst); ARIAD; Array BioPharma (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Genentech; Jounce Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Tesaro (Inst)
 
Mimi I-Nan Hu
Consulting or Advisory Role - Blueprint Medicines; Loxo
Speakers' Bureau - Blueprint Medicines
 
Viola Weijia Zhu
Stock and Other Ownership Interests - TP Therapeutics (I)
Honoraria - AstraZeneca; Roche/Foundation Medicine; Roche/Genentech; Takeda
Consulting or Advisory Role - TP Therapeutics
Speakers' Bureau - AstraZeneca; Roche/Foundation Medicine; Roche/Genentech; Takeda
 
Gilberto Lopes
Consulting or Advisory Role - Pfizer
Research Funding - AstraZeneca; AstraZeneca (Inst); Bavarian Nordic (Inst); Blueprint Medicines (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Merck Sharp & Dohme (Inst); NOVARTIS (Inst); Tesaro (Inst)
 
Sophie Leboulleux
Research Funding - Genzyme (Inst); Novartis (Inst)
 
Marcia S. Brose
Honoraria - Bayer
Consulting or Advisory Role - AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Eisai; Genzyme; Loxo; Novartis
Research Funding - Bayer (Inst); Blueprint Medicines (Inst); Eisai (Inst); Exelixis (Inst); Loxo (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Martin H. Schuler
Honoraria - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; MSD; Novartis; Pierre Fabre
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Novartis; Roche
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Highly sensitive method for mutation detection by PCR (Inst)
 
Daniel W. Bowles
Stock and Other Ownership Interests - Bristol-Myers Squibb; Gilead Sciences
 
Dong-Wan Kim
Research Funding - Alpha Biopharma (Inst); AstraZeneca/MedImmune (Inst); Hanmi (Inst); Janssen (Inst); Merus (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst); TP Therapeutics (Inst); Xcovery (Inst); Yuhan (Inst)
 
Christina S Baik
Consulting or Advisory Role - AstraZeneca; Novartis
Research Funding - AstraZeneca (Inst); Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Loxo (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst)
 
Elena Garralda
Consulting or Advisory Role - Boehringer Ingelheim; Ellipses Pharma; Janssen; NeoMed; Roche
Speakers' Bureau - MSD
Research Funding - Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Glycotope GmbH; Glycotope GmbH; Menarini
 
Chia-Chi Lin
Honoraria - Daiichi Sankyo; Novartis; Roche
Consulting or Advisory Role - Blueprint Medicines; Boehringer Ingelheim; Novartis
Travel, Accommodations, Expenses - BeiGene; Daiichi Sankyo; Lilly; Novartis
 
Douglas Adkins
Consulting or Advisory Role - Celgene; Lilly; Loxo; Merck; Pfizer
Research Funding - AstraZeneca (Inst); Atara Biotherapeutics (Inst); Celgene (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
Debashis Sarker
Honoraria - Bayer; Ipsen; Pfizer; Pfizer (I)
Consulting or Advisory Role - Eisai; Eisai (I); Ipsen (I); Novartis
Travel, Accommodations, Expenses - Bayer; ipsen; MiNA Therapeutics
 
Giuseppe Curigliano
Honoraria - Ellipses Pharma
Consulting or Advisory Role - Bristol-Myers Squibb; Foundation Medicine; Lilly; Novartis; Pfizer; Roche/Genentech; Samsung
Speakers' Bureau - Foundation Medicine; Lilly; Novartis; Pfizer; Roche/Genentech; Samsung
Travel, Accommodations, Expenses - Pfizer; Roche/Genentech
 
Hui Zhang
Employment - Blueprint Medicines
Stock and Other Ownership Interests - Blueprint Medicines
 
Corinne Clifford
Employment - Blueprint Medicines
Stock and Other Ownership Interests - Blueprint Medicines
 
Christopher D. Turner
Employment - Blueprint Medicines; Celldex
Stock and Other Ownership Interests - Blueprint Medicines; Celldex
 
Vivek Subbiah
Consulting or Advisory Role - MedImmune
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Takeda (Inst); Vegenics (Inst)
Travel, Accommodations, Expenses - Bayer; PharmaMar